Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)
Open accessAbstract
Key Points: First prospective US cooperative trial group in preneoplastic gammopathies. Prospective demonstration that genomic features of preneoplastic cells predict disease risk.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MGUS/SMM may have distinct gene expression signatures capable of predicting progression to MM.
“From the transcriptomic point of view, it has been shown that MGUS/SMM may have distinct gene expression signatures capable of predicting progression to MM.89,90”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [89]
The Discussion (page unavailable) says the GEP-70 gene-expression score independently predicted progression from asymptomatic multiple myeloma (SMM) to clinical myeloma. It also says most predictive utility was in SMM and that further study is needed to establish its utility in MGUS, so prediction for MGUS is not established by this paper. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,367 · see citing works
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,338 · see citing works
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475 · see citing works
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171 · see citing works
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, P., Hanamura, I., Gupta, S. K., Epstein, J., Yaccoby, S., Sawyer, J. R., Burington, B. E., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,137 · see citing works
Self-citationLandgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127 · see citing works
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921 · see citing works
Shaughnessy, J. D., Zhan, F., Burington, B. E., Huang, Y., Colla, S., Hanamura, I., Stewart, P., Kordsmeier, B., Randolph, C. E., Williams, D. R., et al. (2006) · Blood · doi:10.1182/blood-2006-07-038430 · Cited by 916 · see citing works
Self-citationInternational Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J. W., Shaughnessy, J. D., Gutierrez, N. C., Stewart, A. K., Morgan, G. J., Ness, B. V., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886 · see citing works
Self-citationKyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Bladé, J., Merlini, G., Kröger, N. M., Einsele, H., Vesole, D. H., Dimopoulos, M. A., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 886 · see citing works
Self-citationMultiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818 · see citing works
Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia · doi:10.1038/leu.2008.307 · Cited by 815 · see citing works
Self-citationRajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J., Bradwell, A. R., Clark, R. J., Larson, D. R., Plevak, M. F., Dispenzieri, A. A., & Katzmann, J. A. (2005) · Blood · doi:10.1182/blood-2005-03-1038 · Cited by 699 · see citing works
Pérez-Persona, E., Vidriales, M.-B., Mateo, G., García-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martín-Nuñez, G., Alonso, J. M., de las Heras, N., et al. (2007) · Blood · doi:10.1182/blood-2007-05-088443 · Cited by 579 · see citing works
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568 · see citing works
Hanamura, I., Stewart, P., Huang, Y., Zhan, F., Santra, M., Sawyer, J. R., Hollmig, K. A., Zangari, M., Pineda‐Roman, M., van Rhee, F., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009910 · Cited by 479 · see citing works
Self-citationDispenzieri, A. A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D. R., Benson, J. T., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2007) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 432 · see citing works
Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
Walker, R. C., Barlogie, B., Haessler, J., Tricot, G. J. K., Anaissie, E. J., Shaughnessy, J. D., Epstein, J., Hemert, R. L. V., Eren, E., Hoering, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5803 · Cited by 415 · see citing works
Self-citationHillengaß, J., Fechtner, K., Weber, M. D., Bäuerle, T., Ayyaz, S., Heiß, C., Hielscher, T., Moehler, T. M., Egerer, G., Neben, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5356 · Cited by 380 · see citing works
Cesana, C., Klersy, C., Barbarano, L., Nosari, A., Crugnola, M., Pungolino, E. M., Gargantini, L., Granata, S., Valentini, M., & Morra, E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1625 · Cited by 257 · see citing works
Rajkumar, S. V., Gupta, V, Fonseca, R., Dispenzieri, A., Gonsalves, W. I., Larson, D., Ketterling, R. P., Lust, J. A., Kyle, R. A., & Kumar, S. K. (2013) · Leukemia · doi:10.1038/leu.2013.86 · Cited by 239 · see citing works
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
Larsen, J. T., Kumar, S. K., Dispenzieri, A. A., Kyle, R. A., Katzmann, J. A., & Rajkumar, S. V. (2012) · Leukemia · doi:10.1038/leu.2012.296 · Cited by 239 · see citing works
Thalidomide as initial therapy for early-stage myeloma
Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Fonseca, R., Geyer, S. M., Iturria, N. L., Kumar, S. K., Lust, J. A., Kyle, R. A., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402866 · Cited by 225 · see citing works
Hose, D., Rème, T., Hielscher, T., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.030296 · Cited by 199 · see citing works
Špíšek, R., Kukreja, A., Chen, L.-C., Matthews, P., Mazumder, A., Vesole, D. H., Jagannath, S., Zebroski, H. A., Simpson, A. J. G., Ritter, G., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062387 · Cited by 199 · see citing works
Self-citationKyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., & Melton, L. J. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.859 · Cited by 194 · see citing works
Zhan, F., Tian, E., Bumm, K., Smith, R., Barlogie, B., & Shaughnessy, J. D. (2003) · Blood · doi:10.1182/blood-2002-06-1737 · Cited by 166 · see citing works
Self-citationKastritis, E., Terpos, E., Moulopoulos, L. A., Spyropoulou‐Vlachou, M., Kanellias, N., Eleftherakis-Papaiakovou, E., Gkotzamanidou, M. A., Migkou, M., Gavriatopoulou, M., Ρούσσου, Μ., et al. (2012) · Leukemia · doi:10.1038/leu.2012.309 · Cited by 155 · see citing works
Smoldering multiple myeloma: natural history and recognition of an evolving type
Rosiñol, L., Bladé, J., Esteve, J., Aymerich, M., Rozman, M., Montoto, S., Giné, E., Nadal, E., Filella, X., Queralt, R., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04654.x · Cited by 151 · see citing works
Mitsiades, C. S., McMillin, D. W., Klippel, S., Hideshima, T., Chauhan, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.007 · Cited by 125 · see citing works
Bladé, J., Dimopoulos, M. A., Rosiñol, L., Rajkumar, S. V., & Kyle, R. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2257 · Cited by 115 · see citing works
Barlogie, B., van Rhee, F., Shaughnessy, J. D., Epstein, J., Yaccoby, S., Pineda‐Roman, M., Hollmig, K. A., Alsayed, Y. M., Hoering, A., Szymonifka, J. D., et al. (2008) · Blood · doi:10.1182/blood-2008-06-164228 · Cited by 102 · see citing works
Self-citationModeling progression risk for smoldering multiple myeloma: results from a prospective clinical study
Cherry, B. M., Korde, N., Kwok, M., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.764419 · Cited by 100 · see citing works
Moreau, P., Attal, M., Garban, F., Hulin, C., Facon, T., Marit, G., Michallet, M., Doyen, C., Leyvraz, S., Mohty, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404832 · Cited by 88 · see citing works
Many Multiple Myelomas: Making More of the Molecular Mayhem
Chesi, M., & Bergsagel, P. L. (2011) · Hematology · doi:10.1182/asheducation-2011.1.344 · Cited by 52 · see citing works
Terpstra, W. E., Lokhorst, H. M., Blomjous, F. J. E. M., Meuwissen, O. J., & Dekker, A. W. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb04592.x · Cited by 50 · see citing works
Some Exploratory Tools for Survival Analysis
Crowley, J., LeBlanc, M. L., Jacobson, J. L., et al. (1997) · Lecture notes in statistics · doi:10.1007/978-1-4684-6316-3_11 · Cited by 26 · see citing works
Self-citationNeben, K., Jauch, A. S., Hielscher, T., Hillengaß, J., Lehners, N., Raab, M. S., Ho, A. D., Goldschmidt, H., & Hose, D. (2012) · Blood · doi:10.1182/blood.v120.21.1806.1806 · Cited by 3 · see citing works
Multiple imputation of missing blood pressure covariates in survival analysis
van Buuren, S., Boshuizen, H. C., & Knook, D. L. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6
Flagged first, then by citations
Research works printed but not linked: 4
- [8]Alexanian R. Localized and indolent myeloma. Blood. 1980;56(3):521–525. [PubMed] [Google Scholar]
- [20]Cox DR. Regression and life tables. Stat Soc. 1972;34:187–202. [Google Scholar]
- [22]LeBlanc M, Crowley J. Survival by goodness of split. J Am Stat Assoc. 1993;88:457–467. [Google Scholar]
- [23]Xu R, O'Quigley JA. R2 type measure of dependence for proportional hazards models. J Nonparametr Statist. 1999;12:83–107. [Google Scholar]
Cited by
Sorted by citations
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · see citing works
Self-citationBustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00437 · Cited by 187 · see citing works
Termini, R., Žihala, D., Terpos, E., Perez-Montaña, A., Jelínek, T., Raab, M., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1594 · Cited by 54 · see citing works
Evolution of Multiple Myeloma from a Genomic Perspective
Maura, F., Samur, M., & Munshi, N. (2026) · Blood · doi:10.1182/blood.2024026313 · Cited by 8 · see citing works
- Authors
- Dhodapkar, M. V., Sexton, R., Waheed, S., Usmani, S., Papanikolaou, X., Nair, B., Petty, N., Shaughnessy, J. D., Hoering, A., Crowley, J., Orlowski, R. Z., & Barlogie, B.
- Affiliations
- Yale Cancer Center (US)
- Cancer Research And Biostatistics (US)
- University of Arkansas for Medical Sciences (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-01-02
- Volume
- 123
- Issue
- 1
- Pages
- 78-85
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3879908
- OpenAlex
- W1968121313
- Cited by
- 192
- References
- 39
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 13 · 2023: 18 · 2022: 7 · 2021: 21 · 2020: 16 · 2019: 13 · 2018: 18 · 2017: 17 · 2016: 15 · 2015: 19 · 2014: 28
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services
- National Institutes of Health (2u10ca038926-25)
- National Cancer Institute (U10CA004919, R01CA135110, CA-11083, CA 68183, N01 CA035176, CA-76462, CA-46282, CA37981, CA 20319, N01 CA027057, N01 CA038926, CA58416, U10CA068183, U10CA058882, N01 CA004919, N01 CA032102, U10-CA038926, CA-12644, U10CA027057, U10CA020319, U10CA011083, CA-58882, P01CA055819, U10CA035119, U10CA032102, U10CA046282, U10CA012644, R01CA106802, U10CA058416, N01 CA046441, U10CA035176, CA-76447, U10CA037981, N01 CA035119, U10CA076447, P30CA016672, U10CA046441)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- multiple myeloma, monoclonal gammopathy of undetermined significance, asymptomatic multiple myeloma, disease progression, gene expression profiles, free light chains, M-spike, focal lesions, magnetic resonance imaging, molecular subtypes, risk prediction
- MeSH terms
- Aged, Female, Humans, Immunoglobulin Light Chains, Magnetic Resonance Imaging, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Prospective Studies, Risk, Time Factors, Cohort Studies, Proportional Hazards Models, Disease Progression, Syndecan-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
